The VESPA study group includes:

3331 words (including abstract) 2 tables 2 Objectives: Benefits from HAART may be heterogeneous across HIV-infected individuals. We measured the differences in the rate of HAART failure across the various subgroups represented at the level of a country. Design: We used data from a national representative sample of people living with HIV and followed at hospital in France (ANRS-EN12-VESPA survey). Methods: Analyses were restricted to the 896 participants on HAART for ≥6 months and antiretroviral-naïve at HAART initiation. Different indicators of treatment failure were defined: immunologic failure (absence of increase of ≥100 CD4 cell/mm 3); immuno-virologic failure (CD4 cell count≤200/mm